We Offer Worldwide Shipping
Login Wishlist

Deferasirox

$125

  • Brand : BIOFRON

  • Catalogue Number : BN-O1221

  • Specification : 99%(HPLC)

  • CAS number : 201530-41-8

  • Formula : C21H15N3O4

  • Molecular Weight : 373.36

  • PUBCHEM ID : 5493381

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1221

Analysis Method

Specification

99%(HPLC)

Storage

-20℃

Molecular Weight

373.36

Appearance

Powder

Botanical Source

Structure Type

Category

SMILES

C1=CC=C(C(=C1)C2=NN(C(=N2)C3=CC=CC=C3O)C4=CC=C(C=C4)C(=O)O)O

Synonyms

ICL-670/Exjade/Deferasirox

IUPAC Name

Density

1.4±0.1 g/cm3

Solubility

Flash Point

360.3±34.3 °C

Boiling Point

672.1±65.0 °C at 760 mmHg

Melting Point

260-262ºC

InChl

InChl Key

FMSOAWSKCWYLBB-VBGLAJCLSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:201530-41-8) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

29999871

Title

Deferasirox

Publish date

2019 Feb 7.

PMID

29071014

Abstract

Thallium and its compounds are a class of highly toxic chemicals that cause wide-ranging symptoms such as gastrointestinal disturbances; polyneuritis; encephalopathy; tachycardia; skin eruptions; hepatic, renal, cardiac, and neurological toxicities; and have mutagenic and genotoxic effects. The present research aimed to evaluate the efficacy of the chelating agents deferasirox (DFX) and deferiprone (L1) in reducing serum and tissue thallium levels after the administration of thallium (III), according to two different dosing regimens, to several groups of Wistar rats for 60 days. It was hypothesized that the two chelators might be more efficient as a combined therapy than as monotherapies in removing thallium (III) from the rats’ organs. The chelators were administered orally as either single or combined therapies for a period of 14 days. Serum and tissue thallium (III) and iron concentrations were determined by flame atomic absorption spectroscopy. Serum and tissue thallium (III) levels were significantly reduced by combined therapy with DFX and L1. Additionally, iron concentrations returned to normal levels and symptoms of toxicity decreased.

KEYWORDS

Thallium (III), Chelation therapy, Deferasirox, Deferiprone, Toxic metal, Serum

Title

Chelation of Thallium (III) in Rats Using Combined Deferasirox and Deferiprone Therapy

Author

Samie Salehi, Amir Sh. Saljooghi, Somayeh Badiee, and Mojtaba Mashmool Moqadam

Publish date

2017 Oct;

PMID

23887830

Abstract

Iron overload is a major health problem for patients who have to have continuous blood transfusions. It brings some metabolic problems together. Various iron chelating agents are being used for treatment of hemochromatosis which arises from excess iron accumulation. This study was conducted with the aim of determining whether deferasirox used as an iron chelator in patients with hemochromatosis has genotoxic effects. Commercial form of deferasirox, Exjade was used as test material. Test material showed a general mutagen character in mutant strains of Salmonella typhimurium. Deferasirox has also led to an increase in mutagenity-related polymorphic band count in random amplification of polymorphic DNA test done with bone marrow cells of rats. Similarly, test material has increased micronucleus formation in cultured in vitro human peripheral lymphocytes particularly in 48 h period. Consistently with the abovementioned findings, deferasirox reduced nuclear division index (NDI) compared to controls and some part of these reductions are statistically significant. NDI reductions were found at positive control levels at high concentrations.

KEYWORDS

Iron chelator, Deferasirox, Genotoxicity, Reversion test, RAPD test, Micronucleus test

Title

Signs of deferasirox genotoxicity

Author

Hasan Basri Ila,corresponding author Mehmet Topaktas, Mehmet Arslan, and Mehmet Buyukleyla

Publish date

2014 Aug;


Description :

Empty ...